Ok, so the basis for your opinion is simply the value of other companies??? That is a poor way to calculate valuation. Instead, try using numbers and information that are relevant.
1. We know that the potential addressable market for solid tumor cancer is millions of cases.
2. We know that NWBO believes their platform is potentially applicable to that market (they even put it on a presentation slide which was shared on this board recently).
3. We know that the current P3 trial is targeting both newly diagnosed GBM patients and recurrent GBM patients. That combined market is quite large.
4. IF (with the help of Flaskworks technology) they can be in a position by the end of 2022 to treat 75,000 patients in 2023 that would lead to a price per share of about $173.44 using a 1.2 billion outstanding share count.
Here are the assumptions to support that math:
$185,000 price per patient
75,000 patients projected to be treated in 2023
1.2 Billion shares outstanding
15 multiple
$173.44/share
If you are more pessimistic and assume capacity and demand for just 30,000 patients per yr the result would be $69.38/share.
People simply throw out numbers without any basis. I would not be surprised at all if the company can ramp to capacity for more than 30,000 by the end of 2022/beginning of 2023.
Happy New Yr!
News 
Market Data 
Discover 
AI
